Buscar ubicaciones
Para conocer los horarios, visitas sin turno y citas.No se pudo cargar la navegación global.
Synonyms
- Labcorp Plasma Focus
- Liquid Biopsy
Special Instructions
Specimens must be submitted using the Liquid Biopsy Specimen Kit and shipped directly to the PGDx lab location, using the shipping label provided in the kit.
This assay currently is not available in New York state.
|
Specimens must be submitted using the Liquid Biopsy Specimen Kit and shipped directly to the PGDx lab location, using the shipping label provided in the kit. <. |
|
Specimens must be submitted using the Liquid Biopsy Specimen Kit and shipped directly to the PGDx lab location, using the shipping label provided in the kit. This assay currently is not available in New York state. |
Expected Turnaround Time
7 - 10 days
Turnaround time is defined as the usual number of days from the date of pickup of a specimen for testing to when the result is released to the ordering provider. In some cases, additional time should be allowed for additional confirmatory or additional reflex tests. Testing schedules may vary.
Specimen Requirements
Specimen
Whole blood
Volume
2 tubes of 10 mL each
Minimum Volume
2 tubes of 10 mL each
Container
Liquid Biopsy Specimen Kit (PeopleSoft No. 137408)
Collection
Collect 10 mL of whole blood into each of 2 Streck BCT tubes supplied in the Liquid Biopsy Specimen Kit. Only the Liquid Biopsy Specimen Kit can be used for collection.
Storage Instructions
Maintain at room temperature after collection and during shipping.
Stability Requirements
| Temperature | Period |
|---|---|
| Room temperature | 7 days |
| Refrigerated | 0 days |
| Frozen | 0 days |
Causes for Rejection
Samples not collected and submitted in Streck tubes; specimens submitted in expired or incorrect blood tubes; quantity not sufficient for analysis; specimens received more than seven days from collection; frozen specimens
Test Details
Use
The Labcorp Plasma Focus test is a Next Generation Sequencing-based laboratory-developed test (LDT) for the detection of genomic sequence mutations in 33 clinically actionable or relevant genes, including amplifications in eight genes, translocations associated with five genes and microsatellite instability (MSI) using plasma derived cell DNA (cfDNA). The test is intended to be used by qualified health care professionals in accordance with professional oncology guidelines for patients with advanced stage or metastatic non small cell lung cancer, colorectal cancer, breast cancer, esophageal cancer, gastroesophageal junction cancer, gastric cancer or melanoma. Test results are not prescriptive for the use of any specific therapeutic product.
Methodology
Next Generation Sequencing
LOINC® Map
© 2021 Laboratory Corporation of America® Holdings and Lexi-Comp Inc. All Rights Reserved.
CPT Statement/Profile Statement
The LOINC® codes are copyright © 1994-2021, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. Permission is granted in perpetuity, without payment of license fees or royalties, to use, copy, or distribute the LOINC® codes for any commercial or non-commercial purpose, subject to the terms under the license agreement found at https://loinc.org/license/. Additional information regarding LOINC® codes can be found at LOINC.org, including the LOINC Manual, which can be downloaded at LOINC.org/downloads/files/LOINCManual.pdf